91 results about "Hepatocyte growth factor" patented technology

The invention relates to the technical field of stem cell injections, in particular to a human umbilical cord mesenchymal stem cell injection and a preparation method thereof. The cell cryoprotectant comprises the following components: a cell cryoprotectant and P6-generation human umbilical cord mesenchymal stem cells. By selecting P6-generation human umbilical cord mesenchymal stem cells, the capacity of secreting hepatocyte growth factors (HGF) can be improved; the cell cryoprotectant contains 6-9wt% of dimethyl sulfoxide and a certain amount of human serum albumin, can better protect cells and maintain the motility rate and biological functions of the cells, and is more beneficial to preparation of cryopreserved human umbilical cord mesenchymal stem cell injection. The P6-generation human umbilical cord mesenchymal stem cells are obtained by culturing a culture medium containing fetal calf serum, and the ability of the injection to repair liver injury can be improved.

The present invention addresses the problem of providing: synovium-derived mesenchymal stem cells that stably exhibit an excellent therapeutic effect on joint diseases; an arthropathy therapeutic agent that contains the synovium-derived mesenchymal stem cells; a method for producing the synovium-derived mesenchymal stem cells; and a method for selecting synovium-derived mesenchymal stem cells for use as an arthropathy therapeutic agent. The present invention provides synovium-derived mesenchymal stem cells that express at least one of a hepatocyte growth factor, a transforming growth factor β-inducing protein, and tumor necrosis factor superfamily 15.

The invention relates to an engineered exosome loaded with specific cytokines as well as a preparation method and application of the engineered exosome, and belongs to a biopharmaceutical technology. The engineered exosome is prepared by the following steps: (1) constructing an expression vector or lentivirus carrying an artificially optimized coding gene of a hepatocyte growth factor; (2) transfecting host cells, and screening successfully transfected host cells; (3) carrying out amplification culture on the selected transfected host cells, and separating and collecting exosomes of the transfected host cells; the expression vector is a transient expression vector or a lentiviral vector; an ExoBoost cell is adopted as the host cell. Experimental data show that the engineered exosome provided by the invention can promote hair follicle growth and has the application potential of improving AGA symptoms.

Provided herein are genetically-modified cells such as pluripotent stem cells and mesenchymal stem cells and methods for producing the same. The gene editing strategy of the present disclosure achieves high expression of a transgene in the genetically modified cells.

Provided are: a culture medium which is for producing an organoid and which comprises a prostaglandin, hepatocyte growth factor (HGF), an interleukin (IL)-6 family protein, and an epidermal growth factor (EGF) family protein; a kit for cultivating an organoid; a method for producing an organoid; and an organoid.

The embodiment of the present invention discloses an induction culture medium, method and application for improving the viability and factor secretion ability of hair follicle-derived mesenchymal stem cells in a hypoxic environment. The induction culture medium includes a basal culture medium and an induction drug, and the induction drug includes transforming growth factor β, hepatocyte growth factor, cyclic adenosine monophosphate, triptolide, sodium hydrosulfide, lipopolysaccharide, hyaluronic acid, dexamethasone, L-glutamine and HEPES buffer. The induction culture medium provided by the present invention can promote the metabolism and energy production of hair follicle-derived mesenchymal stem cells, enhance the antioxidant capacity of cells, improve the survival rate and factor secretion ability of cells in a hypoxic environment, and solve the problems of low cell viability, slow growth, low cytokine secretion, etc. after transplanting cells into damaged tissue areas in the prior art.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention provides an agent for protecting and regenerating pancreatic beta cells in a mammal having diabetes, the agent containing a recombinant viral vector that expresses hepatocyte growth factor (HGF), wherein the agent is characterized by being administered in a dose of 1010-1012 virus particles (vp) / kg body weight, and by the virus vector including a nucleic acid that encodes HGF downstream of a promoter having transcription activity capable of yielding a therapeutically effective HGF level in the blood at said dose.

The invention discloses a method for detecting the content of hepatocyte growth factors of mesenchymal stem cells, and belongs to the technical field of protein detection. The method comprises the steps that an MSC cell suspension with the known concentration is taken, the MSC cell suspension and a cell lysis solution are mixed according to the set volume ratio and matched with a direct lysis technology to prepare a to-be-detected sample, and the lysis solution is prepared from disodium hydrogen phosphate, TritonX-100, NP-40 and SDS with the specific content. The lysate does not influence the combination of the antigen and the antibody, so that the content of the HGF of the mesenchymal stem cells is detected by adopting ELISA (enzyme-linked immunosorbent assay) and can be used as an important biological function index for evaluating MSC (mesenchymal stem cells) immunoregulation, tissue repair and cell apoptosis inhibition. The method is simple, convenient and efficient, compared with a traditional repeated freezing and thawing sample preparation method, the sample preparation period is greatly shortened, the sample cracking efficiency is improved, and a better sample preparation method is provided for detecting the protein content of the mesenchymal stem cells.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

The present invention provides a primary cell culture medium for culturing primary lung cancer epithelial cells, which contains at least one of an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, a fibroblast growth factor 7, a B27 supplement, and a N2 supplement, a hepatocyte growth factor, an insulin-like growth factor 1, an interleukin 6, and a TGFβ type I receptor inhibitor. The present invention also relates to a culturing method using the primary cell culture medium and its application in drug efficacy evaluation and screening. The culturing method uses the above-mentioned primary cell culture medium to culture primary cells on a culture vessel coated with extracellular matrix glue, so that the primary cells proliferate rapidly. The cell model obtained by the primary cell culture medium and the primary cell culturing method of the present invention can be used for drug efficacy evaluation and screening.

A treated human umbilical cord composition for use in the treatment of Perony's disease by in vivo injection in a subject in need thereof using an effective amount of the composition. The composition comprises a water-based human umbilical cord filtrate, wherein endogenous hyaluronic acid (HA) and / or hyaluronic acid, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycan (sGAG), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, metalloproteinase tissue inhibitor 1 (TIMP-1), and / or a pharmaceutically acceptable salt thereof in an amount effective to reduce the size of Pteroid disease plaques. The present invention relates to an aggregation glycan, or a combination thereof.

The invention provides an injection for inducing mesenchymal stem cells. The induced mesenchymal stem cell injection is prepared from induced mesenchymal stem cells modified by hepatocyte growth factors with the cell density being 1.0 * 10 < 5 >-2.0 * 10 < 7 > / ml, HSA with the mass concentration being 0.25%-6%, DMSO with the mass concentration being 5%-10%, glucose with the mass concentration being larger than 0 and smaller than 1%, compound amino acid with the concentration being 0.5-5 mg / mL and the balance compound electrolyte injection. And the induced mesenchymal stem cell injection has a pH value of 6.8 to 7.5. The induced mesenchymal stem cell injection is good in homogeneity, small in batch difference and stable in curative effect, can effectively promote damaged tissue repair, can be directly intravenously injected after cryopreservation and recovery, keeps high cell viability and drug activity, achieves an excellent treatment effect, has good room-temperature stability, is convenient to transport and store, and is suitable for clinical application. The method is suitable for different clinical application occasions, and the clinical application range of the mesenchymal stem cells is expanded.

The present invention relates to an AAV (adeno-associated virus) vector into which a hepatocyte growth factor gene optimized for intrathecal administration has been introduced. The AAV vector of the present invention and the AAV particles produced thereby are excellent in productivity of AAV particles containing the hepatocyte growth factor gene, and are also highly efficient in expressing hepatocyte growth factor when administered intrathecally to a mammal. Therefore, when the AAV vector and particles of the present invention are used for intrathecal administration, they can be usefully used for the prevention or treatment of associated diseases by inducing expression of the hepatocyte growth factor protein.

To provide a novel medium for propagating liver organoids that achieves cost reduction compared to conventional media.SOLUTION: The present invention provides a medium for propagating human pluripotent stem cell-derived liver organoids, the medium comprising a culture supernatant of modified L cells, which are L cells modified so as to express R-spondin-1, hepatocyte growth factor (HGF), fibroblast growth factor (FGF) 7, and fibroblast growth factor 10.SELECTED DRAWING: Figure 5

Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including fibrosis.

The invention relates to the technical field of regenerative medicine application, in particular to a serum-free induction culture medium with definite components for promoting adipose tissue-derived cells to be differentiated into dermal papilla cells, an induction method and application. The invention relates to a method for promoting adipose tissue-derived cells to differentiate into dermal papilla cells, which is characterized in that the adipose tissue-derived cells are induced and cultured by using a serum-free induction culture medium, so that the adipose tissue-derived cells are differentiated into the dermal papilla cells. The formula of the serum-free induction culture medium comprises hepatocyte growth factors, hydrocortisone, bone morphogenetic protein 2, BIO and basic fibroblast growth factors. Based on the differentiation potential of adipose tissue-derived mesenchymal cells and the function maintenance mechanism of dermal papilla cells, a serum-free induction system with definite components is constructed, and directional differentiation is realized. According to the technical scheme, the technical problem that a method for inducing the adipose-derived mesenchymal cells to be directionally differentiated into the dermal papilla cells with the effective hair follicle regulation function is lacked in the prior art can be solved, and the method has ideal application and popularization potential.

The present invention provides a culture medium for culturing primary cervical cancer epithelial cells, comprising an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, fibroblast growth factor 7, at least one of a B27 additive and an N2 additive, hepatocyte growth factor, insulin-like growth factor 1, CHIR99021, and a TGFβ type I receptor inhibitor. The present invention also relates to a culture method using the primary cell culture medium and its application. The culture method uses the primary cell culture medium to culture primary cells on a culture vessel coated with extracellular matrix gel, resulting in rapid proliferation of the primary cells. The cultured cells can be used to evaluate or screen drugs for treating cervical cancer.

The present invention relates to a culture medium for culturing esophageal cancer organoids, comprising an MST1 / 2 kinase inhibitor, at least one cell culture additive selected from N2 and B27, hepatocyte growth factor, SB202190, Y27632, A83-01, epidermal growth factor, gastrin, keratinocyte growth factor, GlutaMAX, and nicotinamide. The present invention also relates to a culture method for esophageal cancer organoids and its use. By using the esophageal cancer organoid culture medium of the present invention, effective and rapid expansion of esophageal cancer organoids can be achieved. The expanded organoids retain the patient's pathological characteristics, improve the culture success rate and expansion rate of esophageal cancer organoids, and provide a research basis for personalized treatment of patients.

The invention relates to the technical field of medicines, in particular to application of allogenic liver precursor cells in preparation of a medicine for treating liver cirrhosis, and the liver cirrhosis is decompensated liver cirrhosis. The allogenic liver precursor cells degrade extracellular matrix, fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) through paracrine MMPs to promote hepatocyte regeneration and repair and the like, so that the liver cirrhosis is relieved and improved.

The invention discloses a linear poly (beta-amino ester) compound loaded with hepatocyte growth factors as well as a preparation method and application of the linear poly (beta-amino ester) compound, and belongs to the technical field of biological medicines. The compound is obtained by self-assembly of linear poly beta-amino ester DD90-C12-DMEN and HGF mRNA in a buffer solution, the compound is suitable for aerosol inhalation delivery, higher mRNA transfection efficiency is obtained in lung-related epithelial / stromal cells, macrophages and other cells difficult to transfect, and particularly, the compound shows remarkable transfection advantages on the macrophages.

The invention belongs to the technical field of medicines, and particularly relates to application of a pigment epithelium-derived factor (PEDF) in synergistically enhancing a hepatocyte growth factor (HGF) in resisting pulmonary arterial hypertension (PH). Research finds that the HGF can improve pulmonary artery remodeling in PH, but can aggravate vascular leakage through a VEGF / VEGFR2 pathway. The PEDF can be combined with VEGFR2 (vascular endothelial growth factor receptor 2) to inhibit VEGF-induced endothelial cell activation and permeability increase. Meanwhile, a specific region of the PEDF is combined with the VEGFR2 under the action of a hydrogen bond and the like, and a derivative peptide fragment of the PEDF can block a VEGF / VEGFR2 signal. Compared with single HGF, cotransfection of the PEDF and the HGF can better inhibit angiogenesis and leakage and delay PH progress. Researches prove that the PEDF counteracts the leakage promoting side effect of the HGF through specific binding with the VEGFR2, and a theoretical basis is provided for developing a PH treatment strategy of the HGF combined with the PEDF derived peptide.

Provided herein are genetically modified cells such as pluripotent stem cells and mesenchymal stem cells and methods of making the same. The gene editing strategies of the present disclosure enable high expression of transgenes in genetically modified cells.

This invention relates to the field of biomedical materials technology, providing a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold material, its preparation method, and its applications. The preparation method includes: decellularizing adipose tissue to obtain adipose tissue decellularized scaffold; heparinizing the scaffold to obtain a heparinized adipose tissue decellularized scaffold; loading hepatocyte growth factor and vascular endothelial cell growth factor onto the scaffold to obtain a heparinized dual-growth factor adipose tissue decellularized scaffold; seeding induced pluripotent stem cell-derived hepatocytes onto the scaffold, and culturing to obtain a heparinized dual-growth factor recellularized adipose tissue decellularized scaffold (RAT). This invention uses rat inguinal adipose tissue to prepare RAT material, which is low-cost, readily available, has a simple preparation process, and is easy to scale up. The RAT material of this invention can achieve liver tissue damage repair and hepatocyte regeneration, providing a new treatment strategy for acute liver failure.

Provided is a therapeutic agent for spinal cord injury from acute to subacute phases, particularly a therapeutic agent for severe spinal cord injury, which is difficult to treat in the past. The invention discloses a therapeutic agent for spinal cord injury from an acute stage to a subacute stage. The present invention is characterized by comprising: (1) (a) a hepatocyte growth factor protein or a substance having a c-Met phosphorylation effect equivalent to that of a hepatocyte growth factor protein, or (b) a gene encoding a hepatocyte growth factor protein or a gene encoding a substance having a c-Met phosphorylation effect equivalent to that of a hepatocyte growth factor protein; and (2) pluripotent stem cells.

The present invention relates to an adeno-associated virus (AAV) vector optimized for intrathecal administration into which a hepatocyte growth factor gene is introduced. The AAV vector of the present invention and AAV particles produced through the vector have excellent productivity of AAV particles comprising a hepatocyte growth factor gene, and when administered intrathecally to a mammal, the expression efficiency of hepatocyte growth factor is also very high. Therefore, the AAV vector of the present invention and the AAV particles induce the expression of hepatocyte growth factor protein when administered intrathecally, and thus can be effectively used in the prevention or treatment of related diseases.

The application discloses a kind of serum-free epidermal melanocyte culture medium and its application, method includes by dissolving adenine, hepatocyte growth factor (HGF), glutamine, retinoic acid, vitamin E, nicotinic acid, sodium selenite, sodium hyaluronate and recombination human type XVII collagen are configured into initial culture medium;Preparation of melanocyte stimulating hormone, endothelin-3, transferrin, triiodothyronine, cholesterol, neuroregulin 1 (NRG1), 3-isobutyl-1-methyl purine (IBMX), dibutyryl cyclic adenosine monophosphate (db-cAMP), cholera toxin, hydrocortisone and recombination human insulin mother liquor;Step three: according to culture and concentration, a certain amount of mother liquor of step two is added to initial culture medium.The culture medium can effectively promote human epidermal melanocyte proliferation, melanin accumulation and help to promote human umbilical cord mesenchymal stem cells into human epidermal melanocyte, provide key advantage for obtaining functional melanocyte with high activity and therapeutic potential.

Disclosed is an in vitro method for assessing whether a human subject has periodontitis. The method comprises detecting, in a sample of saliva from said subject, the concentrations of the proteins Hepatocyte Growth Factor (HGF) and Matrix Metalloproteinase 8 (MMP-8). Based on the concentrations determined, and adding age, and possibly other demographic markers such as sex and / or BMI, a testing value reflecting the joint concentrations is determined for said proteins, in combination with one or more demographic markers. The testing value is compared with a threshold value. The threshold reflects in the same manner the joint concentrations and the age, and possibly other demographic markers, as associated with periodontitis and may be seen as an upper limit of testing values as seen in a population of subjects without periodontitis. Thereby a testing value at or above the threshold value is indicative for periodontitis in said subject.

The invention relates to a liver cancer organoid culture medium and application thereof, and belongs to the technical field of medicines. The liver cancer organ-like culture medium disclosed by the invention is prepared from the following components: AdvDMEM F12, HEPES, GlutaMAX, B27, EGF (Epidermal Growth Factor), N-acetyl-L-cysteine, gastrin, HGF (Hepatocyte Growth Factor), FGF-10 (Fibroblast Growth Factor), A83-01, nicotinamide, N2, an adenylate cyclase activator, a three-antibody antibiotic, R-spondin1, Wnt-3a, Y-2763, Noggin, oncostatin M and FGF-23. The culture medium is rich in nutrition and reasonable in component; the liver cancer organoid cell spheres cultured by using the culture medium can stably grow for a long time, continuously amplify and repeatedly cryopreserve. When the culture medium is used for preparing the liver cancer organ model, a foundation is laid for knowing the pathogenesis of liver cancer and screening drugs.

The present invention belongs to the field of stem cell induction differentiation, and specifically relates to a culture medium for multidirectional induction differentiation of amniotic epithelial stem cells and a preparation method thereof. The culture medium of the present invention relates to culture medium I and culture medium II, wherein culture medium I contains stem cell induction stimulator I, plant-derived isorhamnetin and a small amount of hepatocyte growth factor, and stem cell induction stimulator I is prepared from miRNA-141 and modified chitosan, and culture medium I is used to obtain hepatocyte-like cells; culture medium II contains stem cell induction stimulator II, plant-derived rosmarinic acid, bryostatin 1 and a small amount of glial cell-derived neurotrophic factor, and stem cell induction stimulator II is prepared from miRNA-206 and modified chitosan, and culture medium II is used to obtain neuron-like cells. The culture medium obtained by the present invention has a better induction differentiation effect, higher availability, lower toxicity, and less side effects.